Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant

International Journal of Obesity volume 32, pages 1363–1372 (2008)Cite this article

Abstract

Objective:

The severity of obesity is often more determined by the distribution of fat depots rather than by body weight itself. Therefore, the effect of rimonabant on fat distribution pattern was investigated in female candy-fed Wistar rats.

Design:

Female Wistar rats were fed a high fat, high carbohydrate (candy-) diet for 12 weeks. During the last 6 weeks rats were treated with rimonabant. Food intake and body weight development were investigated, as well as effects on total body fat, especially visceral fat and ectopic lipid accumulation in skeletal muscle and liver, determined by in vivo magnetic resonance imaging/magnetic resonance spectroscopy.

Results:

Candy-diet increased body weight, which was predominantly due to the increased total fat mass with predominance of visceral fat accumulation. Treatment with rimonabant fully reversed the weight gain and fat deposition in the visceral cavity and skeletal muscle, in contrast to pair feeding. In spite of an only transient reduction of food intake, body weight reduction, as well as normalized body fat, reduced visceral fat and intramyocellular lipids were maintained over the treatment period.

Conclusions:

We conclude that additional factors other than reduced caloric intake must be responsible for the improvements in these lipid parameters. The complete cluster of results is consistent with increased lipid oxidation caused by rimonabant.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Haslam DW, James WP . Obesity. Lancet 2005; 366/9492: 1197–1209.

    Article  Google Scholar 

  2. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM . Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 2004; 291/23: 2847–2850.

    Article  Google Scholar 

  3. Prentice AM . The emerging epidemic of obesity in developing countries. Int J Epidemiol 2006; 35/1: 93–99.

    Article  Google Scholar 

  4. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C . Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109/3: 433–438.

    Article  Google Scholar 

  5. Cooke D, Bloom S . The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 2006; 5/11: 919–931.

    Article  Google Scholar 

  6. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C . Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10/4: 497–511.

    Article  Google Scholar 

  7. Despres JP, Lemieux I . Abdominal obesity and metabolic syndrome. Nature 2006; 444/7121: 881–887.

    Article  Google Scholar 

  8. Lean ME, Han TS, Morrison CE . Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311/6998: 158–161.

    Article  Google Scholar 

  9. Hofbauer KG, Nicholson JR, Boss O . The obesity epidemic: current and future pharmacological treatments. Annu Rev Pharmacol Toxicol 2007; 47: 565–592.

    Article  CAS  Google Scholar 

  10. Aronne LJ . Is rimonabant a safe and effective treatment for obesity? Nat Clin Pract Endocrinol Metab 2007; 3/5: 388–389.

    Article  Google Scholar 

  11. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350/2–3: 240–244.

    Article  Google Scholar 

  12. Despres JP, Golay A, Sjostrom L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353/20: 2121–2134.

    Article  Google Scholar 

  13. Hollander P . Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am J Med 2007; 120/2 (Suppl 1): S18–S28.

    Article  Google Scholar 

  14. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295/7: 761–775.

    Article  Google Scholar 

  15. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365/9468: 1389–1397.

    Article  Google Scholar 

  16. Jamshidi N, Taylor DA . Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134/6: 1151–1154.

    Article  Google Scholar 

  17. Tucci SA, Rogers EK, Korbonits M, Kirkham TC . The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 2004; 143/5: 520–523.

    Article  Google Scholar 

  18. Di Marzo V, Matias I . Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8/5: 585–589.

    Article  Google Scholar 

  19. Kirkham TC, Williams CM, Fezza F, Di Marzo V . Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136/4: 550–557.

    Article  Google Scholar 

  20. Melis T, Succu S, Sanna F, Boi A, Argiolas A, Melis MR . The cannabinoid antagonist SR 141716A (rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neurosci Lett 2007; 419/3: 231–235.

    Article  Google Scholar 

  21. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63/4: 908–914.

    Article  Google Scholar 

  22. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005; 7/1: 65–72.

    Article  Google Scholar 

  23. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284/2: 345–353.

    Article  Google Scholar 

  24. Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y et al. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 2006; 55/12: 3403–3410.

    Article  Google Scholar 

  25. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA . Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003; 167/1: 103–111.

    Article  Google Scholar 

  26. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W . Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 2008; 149/5: 2557–2566.

    Article  Google Scholar 

  27. Kunnecke B, Verry P, Benardeau A, von KM . Quantitative body composition analysis in awake mice and rats by magnetic resonance relaxometry. Obes Res 2004; 12/10: 1604–1615.

    Article  Google Scholar 

  28. Kuhlmann J, Neumann-Haefelin C, Belz U, Kalisch J, Juretschke HP, Stein M et al. Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats. Diabetes 2003; 52/1: 138–144.

    Article  Google Scholar 

  29. Bergmeyer HU . Methoden der Enzymatischen Analyse. Verlag Chemie: Weinheim, 1974.

    Google Scholar 

  30. Beha A, Juretschke HP, Kuhlmann J, Neumann-Haefelin C, Belz U, Gerl M et al. Muscle type-specific fatty acid metabolism in insulin resistance: an integrated in vivo study in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab 2006; 290/5: E989–E997.

    Article  Google Scholar 

  31. Neumann-Haefelin C, Beha A, Kuhlmann J, Belz U, Gerl M, Quint M et al. Muscle-type specific intramyocellular and hepatic lipid metabolism during starvation in Wistar rats. Diabetes 2004; 53/3: 528–534.

    Article  Google Scholar 

  32. Raun K, von VP, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB . Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56/1: 8–15.

    Article  Google Scholar 

  33. Savage DB, Petersen KF, Shulman GI . Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007; 87/2: 507–520.

    Article  Google Scholar 

  34. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999; 42/1: 113–116.

    Article  Google Scholar 

  35. Arner P . Regional adipocity in man. J Endocrinol 1997; 155/2: 191–192.

    Article  Google Scholar 

  36. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19/11: 1567–1569.

    Article  Google Scholar 

  37. McGarry JD . Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51/1: 7–18.

    Article  Google Scholar 

  38. McGarry JD, Mills SE, Long CS, Foster DW . Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat. Biochem J 1983; 214/1: 21–28.

    Article  Google Scholar 

  39. McGarry JD, Brown NF . The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 1997; 244/1: 1–14.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Therapeutic Department Metabolism, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany

    A W Herling, S Kilp, H-P Juretschke, C Neumann-Haefelin, M Gerl & W Kramer

Authors
  1. A W Herling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Kilp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H-P Juretschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Neumann-Haefelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Gerl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A W Herling.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herling, A., Kilp, S., Juretschke, HP. et al. Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant. Int J Obes 32, 1363–1372 (2008). https://doi.org/10.1038/ijo.2008.105

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2008.105

Keywords

This article is cited by

Search

Advanced search

Quick links